MYMX News and Press, Mymetics Corp From 12/11/19

Anti-retroviral therapy (ART), or highly-active-antiretroviral therapy (HAART), is effective in halting the progression of HIV infection (a disease affecting nearly 40 million persons worldwide). However, HAART does not cure the disease as the HIV virus, despite the treatment, remains hidden in ...

- The second-generation Allergen Immunotherapy based on Anergis Continous Overlapping Peptides (COP) linked to Mymetics Virosomes will be tested by Stallergenes Greer using its therapeutic model of birch allergy - Results of the study are expected in Q1 2020 EPALINGES, SWITZERLAND ...

VANCOUVER, British Columbia , Aug. 1, 2019 /PRNewswire/ -- MYM Nutraceuticals Inc. ("MYM" or the "Company") (CSE: MYM) (CSE: MYM.CN) (OTCBB: MYMMF) is pleased to announce that it has closed a $5.5 million debt financing commitment with Trichome Financial Corp. ("Trichome Financial" or "...

EPALINGES, Switzerland , April 29, 2019 /PRNewswire/ -- Mymetics Corporation (OTCQB: MYMX), a pioneer and leader in the research and development of virosome-based vaccines against life threatening and life disabling diseases, announced today that the National Institutes of Health (NI...

Funding to prepare Mymetics' cold chain-independent needle-free mucosal virosome HIV vaccine candidate for clinical trials Collaboration with Texas Biomedical Institute and University of Louisiana at Lafayette Total award USD 8.67 million over 5 years, with USD 1.9 million budg...